ScholarLens Back to search
2009•Hebei yixueRequires access

The Efficacy and Safety of Trimebutine Maleate in the Treatment of Irritable Bowel Syndrome

Kai Chen

Open publisher page 0 citations

Abstract

Objective: To observe the clinical efficacy and safety of trimebutine maleate in the treatment of the patients with irritable bowel syndrome(IBS).Method: Sixty patients with IBS were given trimebutine maleate 200mg three times a day for four weeks.At the end of treatment,the symptomatic relief was determined.Result: The response rate of the symptomatic relief of abdominal pain in the patients with IBS was 85.7%(48/56),of abdominal distention was 95.7%(44/46),of diarrhea was 71.1%(32/45),and of constipation was 83.3%(5/6) respectively.The total effective rate was 83.4%.No adverse reaction was observed.Conclusion: Trimebutine maleate is a safe and effective drug in the treatment of IBS.

About this research paper

What this paper is about

Objective: To observe the clinical efficacy and safety of trimebutine maleate in the treatment of the patients with irritable bowel syndrome(IBS).Method: Sixty patients with IBS were given trimebutine maleate 200mg three times a day for four weeks.At the end of treatment,the symptomatic relief was determined.Result: The response rate of the symptomatic relief of abdominal pain in the patients with IBS was 85.7%(48/56),of abdominal distention was 95.7%(44/46),of diarrhea was 71.1%(32/45),and of constipation was 83.3%(5/6) respectively.The total effective rate was 83.4%.No adverse reaction was observed.Conclusion: Trimebutine maleate is a safe and effective drug in the treatment of IBS.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective: To observe the clinical efficacy and safety of trimebutine maleate in the treatment of the patients with irritable bowel syndrome(IBS).Method: Sixty patients with IBS were given trimebutine maleate 200mg three times a day for four weeks.At the end of treatment,the symptomatic relief was determined.Result: The response rate of the symptomatic relief of abdominal pain in the patients with IBS was 85.7%(48/56),of abdominal distention was 95.7%(44/46),of diarrhea was 71.1%(32/45),and of constipation was 83.3%(5/6) respectively.The total effective rate was 83.4%.No adverse reaction was observed.Conclusion: Trimebutine maleate is a safe and effective drug in the treatment of IBS.

Key concepts: Medicine, Irritable bowel syndrome, Constipation, Diarrhea, Abdominal pain, Internal medicine, Adverse effect, Gastroenterology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
The Efficacy and Safety of Trimebutine Maleate in the Treatment of Irritable Bowel Syndrome — Research Paper | ScholarLens